FENC FENNEC PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, FENNEC PHARMACEUTICALS INC reported revenue of $17.9M (up 85.2% from a year earlier), net income of $1.97M and diluted EPS of $0.05; over the last four quarters revenue was $59.2M and net income −$9.73B; for the fiscal year ended December 2025 revenue was $44.6M, down 6.1% on the year before.
FENC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $44.6M, gross profit n/a, operating income −$6.28M, net income −$9.74B (margin -21820.3%), EPS −$0.34
- Fiscal year ended Dec 2024: revenue $47.5M, gross profit n/a, operating income $2.57M, net income −$436M (margin -917.2%), EPS −$0.02
- Fiscal year ended Dec 2023: revenue $21.3M, gross profit $20.0M, operating income −$12.8M, net income −$16.0B (margin -75498.8%), EPS −$0.60
- Fiscal year ended Dec 2022: revenue $1.54M, gross profit $1.45M, operating income −$22.6M, net income −$23.7M (margin -1544.9%), EPS −$0.90
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$17.2M, net income −$17.3M (margin n/a), EPS −$0.67
FENC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $17.9M (up 85.2% year over year), net income $1.97M, EPS $0.05
- Quarter ended Mar 31, 2026: revenue $15.1M (up 72.6% year over year), net income $201K, EPS $0.01
- Quarter ended Dec 31, 2025 (from the annual report): revenue $13.8M (up 73.8% year over year), net income −$9.74B, EPS −$0.17
- Quarter ended Sep 30, 2025: revenue $12.5M (up 78.7% year over year), net income −$638K, EPS −$0.02
- Quarter ended Jun 30, 2025: revenue $9.65M (up 32.9% year over year), net income −$3.15M, EPS −$0.11
- Quarter ended Mar 31, 2025: revenue $8.75M (down 65.5% year over year), net income −$1.17M, EPS −$0.04
- Quarter ended Dec 31, 2024 (from the annual report): revenue $7.93M (down 18.6% year over year), net income −$438M, EPS −$0.02
- Quarter ended Sep 30, 2024: revenue $6.97M (up 7.0% year over year), net income −$5.74M, EPS −$0.21
- Quarter ended Jun 30, 2024: revenue $7.26M (up 118.4% year over year), net income −$5.55M, EPS −$0.20
- Quarter ended Mar 31, 2024: revenue $25.4M (up 1413.2% year over year), net income $12.8M, EPS $0.41
- Quarter ended Dec 31, 2023 (from the annual report): revenue $9.74M, net income −$16.0B, EPS −$0.09
- Quarter ended Sep 30, 2023: revenue $6.52M, net income −$1.87M, EPS −$0.07
- Quarter ended Jun 30, 2023: revenue $3.33M, net income −$5.44M, EPS −$0.21
- Quarter ended Mar 31, 2023: revenue $1.68M, net income −$6.05M, EPS −$0.23
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$6.86M, EPS −$0.26
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.09M, EPS −$0.31
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.07M, EPS −$0.19
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.70M, EPS −$0.14
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$4.43M, EPS −$0.18
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.19M, EPS −$0.16
FENC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $27.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$17.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$18.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$14.2M, share buybacks n/a
FENC balance sheet
- Jun 30, 2026: cash $41.2M, total assets $75.8M, total liabilities $33.3M, shareholders' equity $42.4M
- Mar 31, 2026: cash $40.2M, total assets $71.8M, total liabilities $34.1M, shareholders' equity $37.7M
- Dec 31, 2025: cash $36.8M, total assets $70.6M, total liabilities $35.1M, shareholders' equity $35.5M
- Sep 30, 2025: cash $21.9M, total assets $49.3M, total liabilities $53.8M, shareholders' equity −$4.49M
- Jun 30, 2025: cash $18.7M, total assets $44.9M, total liabilities $52.3M, shareholders' equity −$7.46M
- Mar 31, 2025: cash $22.7M, total assets $46.4M, total liabilities $52.3M, shareholders' equity −$5.88M
- Dec 31, 2024: cash $26.6M, total assets $44.9M, total liabilities $50.8M, shareholders' equity −$5.87M
- Sep 30, 2024: cash $40.3M, total assets $58.9M, total liabilities $64.1M, shareholders' equity −$5.17M
What is FENC's revenue?
FENNEC PHARMACEUTICALS INC reported $59.2M of revenue over its last four quarters, through June 30, 2026.
Is FENC profitable?
No. FENNEC PHARMACEUTICALS INC lost $9.73B over the last four quarters.
What is FENC's EPS?
Diluted earnings per share over the last four quarters were −$0.13; $0.05 in the latest quarter.